An ADAM17 inhibitor ZLDI-8 improved the anti-tumor activity of irinotecan in colon cancer cell lines acting in near-additive way and counteracting the induction of Notch1-4 expression by irinotecan [536]. The gene discussed is ADAM17; the disease is neoplasm.